Re:Third member of U.S. FDA advisory panel resigns over Alzh...
by SpicyLemonZest on Friday June 11, 2021 @10:22AM
(#27473745)
Maybe, but it’s not clear to me that the FDA is (or should be) experts in weighing economic incentives for good behavior. There’s plenty of bad economic incentives created by the current FDA process; just ask the Lovaza guys, charging a 10x markup for fish oil. In an ideal world, I don’t think the FDA should have any role in drug approvals other than preventing direct medical harm.
[ Parent
| on HN ]
There are no comments on this comment yet.